Analysis confirms RFS benefit of adjuvant high-dose interferon alpha in melanoma

Source: Healio, November 2019

Adjuvant high-dose interferon-alpha continued to demonstrate improvements in RFS and melanoma-specific survival among patients with resected high-risk melanoma, according to updated results of the randomized E1684, E1690, E1694 and E2696 trials.

Previous study results established high-dose interferon-alpha as standard-of-care adjuvant therapy for this patient population.

The current analysis — conducted after a median 17.9 years for the E1684 trial, 12.2 years for the E1690 trial, 16 years for the E1694 trial, and 16.5 years for the E2696 trial — confirmed the RFS benefit of high-dose interferon-alpha. Additionally, investigators observed a significant difference in melanoma-specific survival among patients treated with high-dose interferon-alpha vs. the ganglioside GM2/keyhole limpet hemocyanin vaccine in the E1694 trial.

Read the original full article

2019 Events

Calculate your risk of getting melanoma Sunscreen calculator
Map of body for recording areas of skin causing you concern on your body Target Therapy Finder